RT Journal Article
SR Electronic
T1 Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.16.23291455
DO 10.1101/2023.06.16.23291455
A1 Reinig, Sebastian
A1 Kuo, Chin
A1 Wu, Chia-Chun
A1 Huang, Sheng-Yu
A1 Yu, Jau-Song
A1 Shih, Shin-Ru
YR 2024
UL http://medrxiv.org/content/early/2024/03/14/2023.06.16.23291455.abstract
AB Various vaccine platforms were developed and deployed against the COVID-19 disease. The Fc-mediated functions of IgG antibodies are essential in the adaptive immune response elicited by vaccines. However, the long-term changes of protein subunit vaccines and their combinations with mRNA vaccines are unknown. A total of 272 serum and plasma samples were collected from individuals who received first to third doses of the protein subunit Medigen, the mRNA (BNT), or the adenovector AstraZeneca vaccines. The IgG subclass level was measured using enzyme-linked immunosorbent assay, and Fc-N glycosylation was measured using LC-MS/MS. Antibody-dependent phagocytosis (ADCP) and complement deposition (ADCD) of anti-spike (S) IgG antibodies were measured. IgG1 and 3 reached the highest anti-S IgG subclass level. IgG1, 2, and 4 subclass levels significantly increased in mRNA- and Medigen-vaccinated individuals. Fc-glycosylation was stable, except in female BNT vaccinees, who showed increased bisection and decreased galactosylation. Female BNT vaccinees had a higher anti-S IgG titer than that of males. ADCP declined in all groups. ADCD increased in Medigen-vaccinated individuals after the third dose. Each vaccine produced specific long-term changes in Fc structure and function. This finding is critical when selecting a vaccine platform or combination to achieve the desired immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (grant number: EMRPD1N0071) and "National Institutes of Health, USA (grant number: U01 AI151698) for the United World Antiviral Research Network (UWARN)."Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Diagnostics Investigational Review Board of Cummaquid, MA, USA gave ethical approval of the sample collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe samples were collected as per protocol SDP-003, Human Biological Specimens Collection, data September 22, 2017 and qualifications of the principal investigator (Robert Pyrtle, M.D.) were reviewed and approved by the Di- agnostics Investigational Review Board (Cummaquid, MA, USA).